STTR Phase I: Electronic Measurement of Capillary Refill Time to Improve Outcomes from Sepsis

该小企业技术转让（STTR）I期项目的更广泛影响/商业潜力是一种通过测量毛细血管再充盈时间（CRT）快速诊断脓毒症的新型外部系统。独立的临床研究已经证明了CRT用于检测脓毒症的实用性。目前用于监测毛细血管再充盈时间的方法依赖于易于人为错误和不一致的物理检查。该公司的目标是开发一种自动诊断和监测设备，用于客观和可重复地量化毛细血管再充盈时间，用于临床环境。如果成功，该技术可能在急诊室，诊所，救护车或家庭中具有广泛的潜在用途。该小型企业技术转让（STTR）第一阶段项目开发了一种新的手指传感器接口，用于监测CRT，确保手指和传感器之间的接触跨越手指尺寸范围，并验证系统在人类使用中的有效性。其目标是确保人为因素工程能够由广泛的护理人员用于广泛的患者。一种新的算法，以提高传感器的性能，并提供用户反馈的噪声或异常信号也将被集成。该系统将在一组有脓毒症风险的患者中进行测试，以证明该器械能够可靠准确地测量各种患者人口统计数据中的CRT，并且该器械易于由各种护理人员（包括医生和家庭成员）使用，无需接受广泛培训。一个成功的第一阶段的结果是一个系统，使一致的能力，收集高质量的措施，CRT的患者在败血症的风险，并为用户提供持续的措施，信号quality.This奖项反映了NSF的法定使命，并已被认为是值得支持，通过评估使用基金会的智力价值和更广泛的影响审查标准。

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is a novel external system for rapidly diagnosing sepsis by measuring capillary refill time (CRT). Independent clinical studies have demonstrated the utility of CRT for detecting sepsis. Current methods for monitoring capillary refill times rely on physical examinations that are both prone to human error and inconsistency. The company aims to develop an automated diagnostic and monitoring device for objectively and repeatably quantifying capillary refill time for use in a clinical setting. If successful, the technology may have widespread potential use in emergency departments, clinics, ambulances, or at home. This Small Business Technology Transfer (STTR) Phase I project develops a new finger-sensor interface for monitoring CRT that ensures contact between the finger and sensor across a range of finger sizes and validate the system in human use. The objectives are to ensure human factors engineering to enable use in a broad range of patients by a wide range of caregivers. A novel algorithm to improve sensor performance and provide user feedback on noise or aberrant signals will also be integrated. The system will be tested in a group of patients at risk for sepsis to demonstrate the device reliably and accurately measures the CRT across a wide variety of patient demographics and the device is easily usable by a wide range of caregivers including physicians and family members without extensive training. A successful Phase I outcome is a system enabling the consistent ability to collect high-quality measures of CRT in patients at risk for sepsis and to provide the user with ongoing measures of signal quality.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.